Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

Most patients support use of AI to help read mammograms with doctor oversight, UTSW survey finds

UT Southwestern Medical Center researchers found that most patients support the use of AI to help interpret mammograms as long as radiologists provide oversight in the imaging analysis, although perceptions varied among patient populations.

January 30, 2026

Vol.52 No.04

Drugs & Targets

Labcorp and Roche collaborate to expand access to advanced precision testing

Labcorp announced its first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.

January 30, 2026

Vol.52 No.04

Drugs & Targets

HanchorBio and WuXi Biologics form partnership to advance next-generation bi-and multi-functional fusion protein pipeline

HanchorBio, a global clinical-stage biotechnology company, and WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization, jointly announced the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.

January 30, 2026

Vol.52 No.04

Drugs & Targets

ACR names University Hospital of Bern first international ARCH AI Site

The American College of Radiology announced that Inselspital, the University Hospital of Bern, Switzerland, is the first international institution to participate in the ACR Recognized Center for Healthcare-AI program for artificial intelligence governance in radiology.

January 30, 2026

Vol.52 No.04

Cancer Policy

FDA releases 10 guiding principles for AI use in drug development

FDA, in collaboration with the European Medicines Agency, has published 10 principles to help guide pharmaceutical companies using artificial intelligence to develop drug, biological, and medical devices.

January 16, 2026

Vol.52 No.02

By Sara Willa Ernst